Skip to content

Ascendis Pharma A/S

ASND· NasdaqCore metricsCIK 1612042

Pharmaceutical preparations551 peers

Last sale
Nov 12, 2026 · +2.89%
Market cap
$16.52B
61.98M shares
Filings
802
€720.13M
FY 2025+98.0% FY25 yoy
-€228.03M
FY 2025N/M FY25 yoy
-€136.27M
FY 2025N/M FY25 yoy
-€220.03M
Q3 2024derivedN/M FY23 yoy
-€3.76
FY 2025N/M FY25 yoy
€616.04M
FY 2025+10.1% FY25 yoy
$16.52B
—
—
—
—
—

Price

$266.47+32.60%+$65.51past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

€720.13MFY 2025
€720.13M0FY 2015FY 2020FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31€720,132,000reported
FY 20242024-12-31€363,641,000reported
FY 20232023-12-31€266,718,000reported
FY 20222022-12-31€51,174,000reported
FY 20212021-12-31€7,778,000reported
FY 20202020-12-31€6,953,000reported
FY 20192019-12-31€13,375,000reported
FY 20182018-12-31€10,581,000reported
FY 20172017-12-31€1,530,000reported
FY 20162016-12-31€4,606,000reported
FY 20152015-12-31€8,118,000reported

Capital returns

Dividends and buybacks · FY2021 to FY2025
Fiscal yearDividendsBuybacksTotalPer shareSharesShares · yoyof free cash flow
FY2025—€17.40M€17.40M—61.98M sh+2.1%—
FY2024—€0.00€0.00—60.69M sh+5.2%—
FY2023—€0.00€0.00—57.71M sh+1.0%—
FY2022—€105.31M€105.31M—57.15M sh+0.4%—
FY2021—€21.61M€21.61M—56.94M sh+5.9%—

Segments

Geography
Revenue by Geography, FY2018 to FY2025FY2018North America · FY2018 · €10.58MFY2019China · FY2019 · €10.72MNorth America · FY2019 · €2.65MFY2020China · FY2020 · €4.27MNorth America · FY2020 · €2.68MFY2021Asia · FY2021 · €922.00KChina · FY2021 · €922.00KNorth America · FY2021 · €6.86MFY2022Europe · FY2022 · €552.00KRest of World · FY2022 · €6.47MAsia · FY2022 · €6.47MChina · FY2022 · €6.47MNorth America · FY2022 · €44.16MFY2023USA · FY2023 · €191.68MEurope · FY2023 · €869.00KRest of World · FY2023 · €74.17MAsia · FY2023 · €74.17MNorth America · FY2023 · €191.68MFY2024USA · FY2024 · €233.12MEurope · FY2024 · €123.34MRest of World · FY2024 · €7.19MDenmark · FY2024 · €95.40MNorth America · FY2024 · €233.22MFY2025USA · FY2025 · €546.39MEurope · FY2025 · €120.95MRest of World · FY2025 · €52.80MDenmark · FY2025 · €12.90M
LineFY2025ShareChange
USA€546.39M76%+134.4%
Europe€120.95M17%−1.9%
Rest of World€52.80M7.3%+634.3%
Denmark€12.90M1.8%−86.5%
Asia———
China———
North America———
Total€720.13M

From the 20-F filed Feb 11, 2026ASND

Pharmaceutical preparations

Ascendis Pharma A/S is the 23rd largest of the 552 covered companies the SEC files under this code, by market cap. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Ascendis Pharma A/S · CIK 1612042 · Engraved from SEC EDGAR